Aragen Life Sciences Ltd., a contract research and manufacturing outfit backed by Quadria, is weighing a public offering in Mumbai. Sources say the float could generate up to $300 million, a scale that would rank it among the larger biotech listings in India this year. The move follows a wave of domestic firms seeking public capital and signal confidence in its growth trajectory.

Investors have watched Aragen’s client roster grow as pharmaceutical companies outsource assay development and small‑batch manufacturing to specialist providers. A public listing would give the firm access to equity markets, potentially lowering its cost of capital and enabling it to scale production capacity. Regulators in Mumbai have streamlined approval processes for biotech IPOs, adding further appeal and improve its competitive positioning.

Should the IPO proceed, Aragen would join a short list of Indian CROs that have tapped capital markets, setting a benchmark for peers considering similar routes. The infusion of Mumbai IPO proceeds could fund new labs, expand geographic reach, and strengthen its balance sheet, positioning the company to capture rising demand for outsourced drug development services in the global market.